A Multi-center, Randomized, Double-blind, Placebo-controlled, Five Period Cross-over Study to Evaluate the Efficacy and Safety of Selected Doses and Dose Intervals of GW642444 Administered Via a Novel Dry Powder Inhaler (NDPI) in Subjects greater than or equal to 18 Years of Age With Persistent Asthma.

Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled, Five Period Cross-over Study to Evaluate the Efficacy and Safety of Selected Doses and Dose Intervals of GW642444 Administered Via a Novel Dry Powder Inhaler (NDPI) in Subjects greater than or equal to 18 Years of Age With Persistent Asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Vilanterol (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 18 May 2011 Results presented at the 107th International Conference of the American Thoracic Society.
    • 17 May 2011 Primary endpoint 'Forced-expiratory-volume-in-1-second' has been met.
    • 20 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top